Personalis, Inc.
PSNLNasdaqHealthcare · Services-Medical Laboratories · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $69.6M | $84.6M | $73.5M | $65.0M | $85.5M | $78.6M |
| Operating income | −$88.1M | −$68.3M | −$109.9M | −$115.5M | −$65.4M | −$42.1M |
| Net income | −$81.3M | −$81.3M | −$108.3M | −$113.3M | −$65.2M | −$41.3M |
| Total assets | $334.2M | $270.3M | $225.1M | $292.7M | $396.5M | $244.8M |
| Total liabilities | $73.0M | $67.3M | $95.7M | $74.6M | $86.2M | $49.9M |
| Equity | $261.2M | $203.0M | $129.4M | $218.1M | $310.3M | $194.9M |
| EPS (diluted) | $-0.91 | $-1.37 | $-2.25 | $-2.48 | $-1.49 | $-1.20 |
| Shares out. | 88.3M | 50.5M | 46.7M | 45.0M | 43.7M | 31.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −126.4%
- Net margin
- −116.7%
- Return on equity
- −31.1%
- Return on assets
- −24.3%
- Return on capital (ROCE)
- −29.9%
- Liabilities / assets
- 21.8%
- Debt / equity
- 0.28×
- Book value / share
- $2.96
- Revenue growth (YoY)
- −17.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 0.31distress
- Accruals / assets
- −1.9%clean
- Beneish M-Score
- -1.28elevated
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 5 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Beneish M-Score elevated — earnings-manipulation screen flag
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 13.7M | 5.6 | +4.8% |
| Apr 30, 2026 | 13.1M | 5.8 | +5.7% |
| Apr 15, 2026 | 12.4M | 9.5 | +5.4% |
| Mar 31, 2026 | 11.8M | 7.4 | +5.3% |
| Mar 13, 2026 | 11.2M | 6.4 | -0.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventMay 20, 2026
- Shareholder voteMay 13, 2026
- Other material eventMay 13, 2026
- Results of operationsMay 7, 2026
- Director / officer changeMar 17, 2026
- Results of operationsFeb 26, 2026
- Results of operationsJan 8, 2026
- Other material eventNov 28, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.